Listed

PharmaCyte Biotech, Inc.

PMCBNasdaqCIK 1157075HealthcareFiscal year ends Apr 30

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q1 FY2027
Operating income−$1.0m, Q1 FY2027
Net income−$5.1m, Q1 FY2027
PharmaCyte Biotech, Inc., income statement, quarterly
Line itemUnitQ2 FY20242023-10-31Q3 FY20242024-01-31Q4 FY20242024-04-30Q1 FY20252024-07-31Q2 FY20252024-10-31Q3 FY20252025-01-31Q4 FY20252025-04-30Q1 FY20262025-07-31Q2 FY20262025-10-31Q3 FY20262026-01-31Q4 FY20262026-04-30Q1 FY20272026-07-31
Revenue$m0.0Revenue, Q2 FY2024, three months to 2023-10-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-01-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2025-08-11, accession 0001683168-25-005821. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2024-07-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure0.0Revenue, Q2 FY2025, three months to 2024-10-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-01-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2025-07-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure0.0Revenue, Q2 FY2026, three months to 2025-10-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure0.0Revenue, Q3 FY2026, three months to 2026-01-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure0.0Revenue, Q4 FY2026, three months to 2026-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2027, three months to 2026-07-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Gross profit$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m0.1Research and development, Q2 FY2024, three months to 2023-10-31$82.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure0.1Research and development, Q3 FY2024, three months to 2024-01-31$126.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure0.1Research and development, Q4 FY2024, three months to 2024-04-30$94.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-08-11, accession 0001683168-25-005821. Derived: 12-month figure less the 9-month figure.Report this figure0.1Research and development, Q1 FY2025, three months to 2024-07-31$96.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure0.1Research and development, Q2 FY2025, three months to 2024-10-31$97.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure0.1Research and development, Q3 FY2025, three months to 2025-01-31$118.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure0.1Research and development, Q4 FY2025, three months to 2025-04-30$126.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure0.1Research and development, Q1 FY2026, three months to 2025-07-31$95.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure0.1Research and development, Q2 FY2026, three months to 2025-10-31$141.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure0.1Research and development, Q3 FY2026, three months to 2026-01-31$93.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure0.1Research and development, Q4 FY2026, three months to 2026-04-30$61.9k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure0.1Research and development, Q1 FY2027, three months to 2026-07-31$60.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Operating income$m(1.4)Operating income, Q2 FY2024, three months to 2023-10-31−$1.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure(1.9)Operating income, Q3 FY2024, three months to 2024-01-31−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure(3.2)Operating income, Q4 FY2024, three months to 2024-04-30−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-08-11, accession 0001683168-25-005821. Derived: 12-month figure less the 9-month figure.Report this figure(1.3)Operating income, Q1 FY2025, three months to 2024-07-31−$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure(1.1)Operating income, Q2 FY2025, three months to 2024-10-31−$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure(1.0)Operating income, Q3 FY2025, three months to 2025-01-31−$960.3k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure(1.0)Operating income, Q4 FY2025, three months to 2025-04-30−$1.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure(0.8)Operating income, Q1 FY2026, three months to 2025-07-31−$848.3k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure(1.4)Operating income, Q2 FY2026, three months to 2025-10-31−$1.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure(2.1)Operating income, Q3 FY2026, three months to 2026-01-31−$2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure(2.5)Operating income, Q4 FY2026, three months to 2026-04-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure(1.0)Operating income, Q1 FY2027, three months to 2026-07-31−$1.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Income tax, Q1 FY2026, three months to 2025-07-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figurenot reportednot reportednot reported0.0Income tax, Q1 FY2027, three months to 2026-07-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Net income$m2.8Net income, Q2 FY2024, three months to 2023-10-31$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure(0.6)Net income, Q3 FY2024, three months to 2024-01-31−$619.5k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure1.3Net income, Q4 FY2024, three months to 2024-04-30$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-08-11, accession 0001683168-25-005821. Derived: 12-month figure less the 9-month figure.Report this figure23.4Net income, Q1 FY2025, three months to 2024-07-31$23.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure(1.5)Net income, Q2 FY2025, three months to 2024-10-31−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure(3.0)Net income, Q3 FY2025, three months to 2025-01-31−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure11.7Net income, Q4 FY2025, three months to 2025-04-30$11.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure(8.4)Net income, Q1 FY2026, three months to 2025-07-31−$8.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure(7.4)Net income, Q2 FY2026, three months to 2025-10-31−$7.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure0.7Net income, Q3 FY2026, three months to 2026-01-31$746.9k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure(4.4)Net income, Q4 FY2026, three months to 2026-04-30−$4.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure(5.1)Net income, Q1 FY2027, three months to 2026-07-31−$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Diluted EPS$ per share(0.26)Diluted EPS, Q2 FY2024, three months to 2023-10-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure(0.65)Diluted EPS, Q3 FY2024, three months to 2024-01-31−$0.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figurenot reported1.90Diluted EPS, Q1 FY2025, three months to 2024-07-31$1.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure(0.39)Diluted EPS, Q2 FY2025, three months to 2024-10-31−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure(0.44)Diluted EPS, Q3 FY2025, three months to 2025-01-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figurenot reported(1.23)Diluted EPS, Q1 FY2026, three months to 2025-07-31−$1.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure(1.24)Diluted EPS, Q2 FY2026, three months to 2025-10-31−$1.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure(0.17)Diluted EPS, Q3 FY2026, three months to 2026-01-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figurenot reported(0.54)Diluted EPS, Q1 FY2027, three months to 2026-07-31−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Basic EPS$ per share(0.26)Basic EPS, Q2 FY2024, three months to 2023-10-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure(0.65)Basic EPS, Q3 FY2024, three months to 2024-01-31−$0.65 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figurenot reported1.90Basic EPS, Q1 FY2025, three months to 2024-07-31$1.90 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure(0.39)Basic EPS, Q2 FY2025, three months to 2024-10-31−$0.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure(0.44)Basic EPS, Q3 FY2025, three months to 2025-01-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figurenot reported(1.23)Basic EPS, Q1 FY2026, three months to 2025-07-31−$1.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure(1.24)Basic EPS, Q2 FY2026, three months to 2025-10-31−$1.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure(0.17)Basic EPS, Q3 FY2026, three months to 2026-01-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figurenot reported(0.54)Basic EPS, Q1 FY2027, three months to 2026-07-31−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure

Balance sheet

Cash and equivalents$17.7m, Q1 FY2027
Shareholders' equity$27.5m, Q1 FY2027
PharmaCyte Biotech, Inc., balance sheet, quarterly
Line itemUnitQ2 FY20242023-10-31Q3 FY20242024-01-31FY20242024-04-30Q1 FY20252024-07-31Q2 FY20252024-10-31Q3 FY20252025-01-31FY20252025-04-30Q1 FY20262025-07-31Q2 FY20262025-10-31Q3 FY20262026-01-31FY20262026-04-30Q1 FY20272026-07-31
Cash and equivalents$m73.4Cash and equivalents, Q2 FY2024, at 2023-10-31$73.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-12-15, accession 0001683168-23-008889.Report this figure61.2Cash and equivalents, Q3 FY2024, at 2024-01-31$61.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-03-18, accession 0001683168-24-001525.Report this figure50.2Cash and equivalents, FY2024, at 2024-04-30$50.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-08-11, accession 0001683168-25-005821.Report this figure32.6Cash and equivalents, Q1 FY2025, at 2024-07-31$32.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-09-17, accession 0001683168-24-006441.Report this figure20.8Cash and equivalents, Q2 FY2025, at 2024-10-31$20.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure16.4Cash and equivalents, Q3 FY2025, at 2025-01-31$16.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure15.2Cash and equivalents, FY2025, at 2025-04-30$15.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure13.2Cash and equivalents, Q1 FY2026, at 2025-07-31$13.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure15.4Cash and equivalents, Q2 FY2026, at 2025-10-31$15.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure20.2Cash and equivalents, Q3 FY2026, at 2026-01-31$20.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure18.6Cash and equivalents, FY2026, at 2026-04-30$18.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure17.7Cash and equivalents, Q1 FY2027, at 2026-07-31$17.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Current assets$m73.7Current assets, Q2 FY2024, at 2023-10-31$73.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-12-15, accession 0001683168-23-008889.Report this figure61.5Current assets, Q3 FY2024, at 2024-01-31$61.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-03-18, accession 0001683168-24-001525.Report this figure50.4Current assets, FY2024, at 2024-04-30$50.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-08-11, accession 0001683168-25-005821.Report this figure32.9Current assets, Q1 FY2025, at 2024-07-31$32.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-09-17, accession 0001683168-24-006441.Report this figure21.3Current assets, Q2 FY2025, at 2024-10-31$21.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure17.0Current assets, Q3 FY2025, at 2025-01-31$17.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure22.4Current assets, FY2025, at 2025-04-30$22.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure19.1Current assets, Q1 FY2026, at 2025-07-31$19.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure23.0Current assets, Q2 FY2026, at 2025-10-31$23.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure20.7Current assets, Q3 FY2026, at 2026-01-31$20.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure37.4Current assets, FY2026, at 2026-04-30$37.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure31.0Current assets, Q1 FY2027, at 2026-07-31$31.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Total assets$m78.9Total assets, Q2 FY2024, at 2023-10-31$78.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-12-15, accession 0001683168-23-008889.Report this figure71.4Total assets, Q3 FY2024, at 2024-01-31$71.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-03-18, accession 0001683168-24-001525.Report this figure59.9Total assets, FY2024, at 2024-04-30$59.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-08-11, accession 0001683168-25-005821.Report this figure70.2Total assets, Q1 FY2025, at 2024-07-31$70.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-09-17, accession 0001683168-24-006441.Report this figure55.1Total assets, Q2 FY2025, at 2024-10-31$55.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure43.8Total assets, Q3 FY2025, at 2025-01-31$43.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure55.2Total assets, FY2025, at 2025-04-30$55.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure45.1Total assets, Q1 FY2026, at 2025-07-31$45.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure56.0Total assets, Q2 FY2026, at 2025-10-31$56.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure55.9Total assets, Q3 FY2026, at 2026-01-31$55.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure46.8Total assets, FY2026, at 2026-04-30$46.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure36.7Total assets, Q1 FY2027, at 2026-07-31$36.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Current liabilities$m5.2Current liabilities, Q2 FY2024, at 2023-10-31$5.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-12-15, accession 0001683168-23-008889.Report this figure7.5Current liabilities, Q3 FY2024, at 2024-01-31$7.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-03-18, accession 0001683168-24-001525.Report this figure7.4Current liabilities, FY2024, at 2024-04-30$7.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-08-11, accession 0001683168-25-005821.Report this figure7.5Current liabilities, Q1 FY2025, at 2024-07-31$7.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-09-17, accession 0001683168-24-006441.Report this figure4.8Current liabilities, Q2 FY2025, at 2024-10-31$4.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure1.2Current liabilities, Q3 FY2025, at 2025-01-31$1.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure2.9Current liabilities, FY2025, at 2025-04-30$2.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure1.1Current liabilities, Q1 FY2026, at 2025-07-31$1.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure1.6Current liabilities, Q2 FY2026, at 2025-10-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure1.7Current liabilities, Q3 FY2026, at 2026-01-31$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure0.8Current liabilities, FY2026, at 2026-04-30$826.4k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure0.8Current liabilities, Q1 FY2027, at 2026-07-31$768.7k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Total liabilities$m20.8Total liabilities, Q2 FY2024, at 2023-10-31$20.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-12-15, accession 0001683168-23-008889.Report this figure22.5Total liabilities, Q3 FY2024, at 2024-01-31$22.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-03-18, accession 0001683168-24-001525.Report this figure20.4Total liabilities, FY2024, at 2024-04-30$20.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-08-11, accession 0001683168-25-005821.Report this figure17.2Total liabilities, Q1 FY2025, at 2024-07-31$17.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-09-17, accession 0001683168-24-006441.Report this figure11.6Total liabilities, Q2 FY2025, at 2024-10-31$11.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure3.6Total liabilities, Q3 FY2025, at 2025-01-31$3.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure3.3Total liabilities, FY2025, at 2025-04-30$3.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure1.5Total liabilities, Q1 FY2026, at 2025-07-31$1.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure19.4Total liabilities, Q2 FY2026, at 2025-10-31$19.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure16.5Total liabilities, Q3 FY2026, at 2026-01-31$16.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure11.8Total liabilities, FY2026, at 2026-04-30$11.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure6.9Total liabilities, Q1 FY2027, at 2026-07-31$6.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m36.8Shareholders' equity, Q2 FY2024, at 2023-10-31$36.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure31.4Shareholders' equity, Q3 FY2024, at 2024-01-31$31.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure27.6Shareholders' equity, FY2024, at 2024-04-30$27.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure47.7Shareholders' equity, Q1 FY2025, at 2024-07-31$47.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure43.5Shareholders' equity, Q2 FY2025, at 2024-10-31$43.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure40.3Shareholders' equity, Q3 FY2025, at 2025-01-31$40.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure51.9Shareholders' equity, FY2025, at 2025-04-30$51.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure43.6Shareholders' equity, Q1 FY2026, at 2025-07-31$43.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure35.2Shareholders' equity, Q2 FY2026, at 2025-10-31$35.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure38.1Shareholders' equity, Q3 FY2026, at 2026-01-31$38.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure33.3Shareholders' equity, FY2026, at 2026-04-30$33.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure27.5Shareholders' equity, Q1 FY2027, at 2026-07-31$27.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure

Cash flow

Operating cash flow−$780.9k, Q1 FY2027
Share repurchases$0, Q4 FY2026
PharmaCyte Biotech, Inc., cash flow, quarterly
Line itemUnitQ2 FY20242023-10-31Q3 FY20242024-01-31Q4 FY20242024-04-30Q1 FY20252024-07-31Q2 FY20252024-10-31Q3 FY20252025-01-31Q4 FY20252025-04-30Q1 FY20262025-07-31Q2 FY20262025-10-31Q3 FY20262026-01-31Q4 FY20262026-04-30Q1 FY20272026-07-31
Operating cash flow$k(1,984)Operating cash flow, Q2 FY2024, three months to 2023-10-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-12-13, accession 0001683168-24-008709. Derived: 6-month figure less the 3-month figure.Report this figure(177)Operating cash flow, Q3 FY2024, three months to 2024-01-31−$177.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-03-17, accession 0001683168-25-001669. Derived: 9-month figure less the 6-month figure.Report this figure(333)Operating cash flow, Q4 FY2024, three months to 2024-04-30−$333.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-08-11, accession 0001683168-25-005821. Derived: 12-month figure less the 9-month figure.Report this figure(373)Operating cash flow, Q1 FY2025, three months to 2024-07-31−$373.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure(1,055)Operating cash flow, Q2 FY2025, three months to 2024-10-31−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-12-18, accession 0001683168-25-009259. Derived: 6-month figure less the 3-month figure.Report this figure(510)Operating cash flow, Q3 FY2025, three months to 2025-01-31−$509.9k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-03-17, accession 0001683168-26-001917. Derived: 9-month figure less the 6-month figure.Report this figure(1,040)Operating cash flow, Q4 FY2025, three months to 2025-04-30−$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure(1,994)Operating cash flow, Q1 FY2026, three months to 2025-07-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure(980)Operating cash flow, Q2 FY2026, three months to 2025-10-31−$979.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-12-18, accession 0001683168-25-009259. Derived: 6-month figure less the 3-month figure.Report this figure(787)Operating cash flow, Q3 FY2026, three months to 2026-01-31−$786.8k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-03-17, accession 0001683168-26-001917. Derived: 9-month figure less the 6-month figure.Report this figure(1,393)Operating cash flow, Q4 FY2026, three months to 2026-04-30−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure(781)Operating cash flow, Q1 FY2027, three months to 2026-07-31−$780.9k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure
Share repurchases$k165Share repurchases, Q2 FY2024, three months to 2023-10-31$165.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2023-12-15, accession 0001683168-23-008889.Report this figure405Share repurchases, Q3 FY2024, three months to 2024-01-31$404.7k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2024-03-18, accession 0001683168-24-001525.Report this figure1,175Share repurchases, Q4 FY2024, three months to 2024-04-30$1.2m. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2025-08-11, accession 0001683168-25-005821. Derived: 12-month figure less the 9-month figure.Report this figure742Share repurchases, Q1 FY2025, three months to 2024-07-31$742.2k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure1,404Share repurchases, Q2 FY2025, three months to 2024-10-31$1.4m. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-12-18, accession 0001683168-25-009259. Derived: 6-month figure less the 3-month figure.Report this figure225Share repurchases, Q3 FY2025, three months to 2025-01-31$225.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-03-17, accession 0001683168-26-001917. Derived: 9-month figure less the 6-month figure.Report this figure172Share repurchases, Q4 FY2025, three months to 2025-04-30$171.5k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure0.0Share repurchases, Q1 FY2026, three months to 2025-07-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure0.0Share repurchases, Q2 FY2026, three months to 2025-10-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-12-18, accession 0001683168-25-009259. Derived: 6-month figure less the 3-month figure.Report this figure402Share repurchases, Q3 FY2026, three months to 2026-01-31$401.6k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-03-17, accession 0001683168-26-001917. Derived: 9-month figure less the 6-month figure.Report this figure0.0Share repurchases, Q4 FY2026, three months to 2026-04-30$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figurenot reported

Shares

Diluted shares (weighted)10.74m, Q1 FY2027
PharmaCyte Biotech, Inc., shares, quarterly
Line itemUnitQ2 FY20232022-10-31Q3 FY20232023-01-31Q1 FY20242023-07-31Q2 FY20242023-10-31Q3 FY20242024-01-31Q1 FY20252024-07-31Q2 FY20252024-10-31Q3 FY20252025-01-31Q1 FY20262025-07-31Q2 FY20262025-10-31Q3 FY20262026-01-31Q1 FY20272026-07-31
Diluted shares (weighted)m shares20.6Diluted shares (weighted), Q2 FY2023, three months to 2022-10-3120,585,451 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-12-15, accession 0001683168-23-008889.Report this figure19.0Diluted shares (weighted), Q3 FY2023, three months to 2023-01-3118,995,442 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-03-18, accession 0001683168-24-001525.Report this figure12.6Diluted shares (weighted), Q1 FY2024, three months to 2023-07-3112,601,891 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-09-17, accession 0001683168-24-006441.Report this figure8.8Diluted shares (weighted), Q2 FY2024, three months to 2023-10-318,765,134 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-12-13, accession 0001683168-24-008709.Report this figure8.6Diluted shares (weighted), Q3 FY2024, three months to 2024-01-318,606,957 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-03-17, accession 0001683168-25-001669.Report this figure7.9Diluted shares (weighted), Q1 FY2025, three months to 2024-07-317,866,387 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-09-15, accession 0001683168-25-006991.Report this figure7.6Diluted shares (weighted), Q2 FY2025, three months to 2024-10-317,637,034 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure7.0Diluted shares (weighted), Q3 FY2025, three months to 2025-01-316,960,014 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure6.8Diluted shares (weighted), Q1 FY2026, three months to 2025-07-316,795,779 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure6.8Diluted shares (weighted), Q2 FY2026, three months to 2025-10-316,795,779 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure9.3Diluted shares (weighted), Q3 FY2026, three months to 2026-01-319,262,829 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure10.7Diluted shares (weighted), Q1 FY2027, three months to 2026-07-3110,735,649 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure

Shares outstanding: 10.74mShares outstanding, period not labelled, at 2026-09-1110,735,649 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure at Sep 11, 2026, from the cover of the 10-Q filed Sep 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.